Novoheart announced the publication of its study in a journal from the International Society for Stem Cell Research.
Novoheart (TSXV:NVH) announced the publication of a new study in a journal from the International Society for Stem Cell Research.
As quoted in the press release:
The study demonstrates how machine learning technology can be leveraged to efficiently analyze rich data content generated from drug screening studies using Novoheart’s bioengineered human heart tissues.
The study was performed in partnership with the University of California, Irvine, the academic base of Novoheart’s scientific co-founder Professor Michelle Khine, and the resulting publication highlights the advantages of utilizing machine learning in comprehending the complex data sets generated when screening drug candidates with Novoheart’s human heart tissue constructs. It was proven to enhance the ability to predict not only the occurrence of drug-induced cardiotoxicity, but also the type of cardiotoxicity, early in the drug discovery process.